ADMA & SMDA

Your arteries stay healthy partly because their inner lining produces a gas called nitric oxide that keeps blood vessels relaxed, flexible, and resistant to fatty buildup. When that system fails, arteries stiffen, blood pressure rises, and atherosclerosis (the buildup of fatty deposits in artery walls) accelerates, often years before standard tests flag a problem. This panel measures two closely related molecules that reveal whether that protective system is breaking down.

Asymmetric dimethylarginine (ADMA) directly interferes with your body's ability to make nitric oxide. Symmetric dimethylarginine (SMDA) reflects how well your kidneys are clearing these toxic byproducts. Measured together, they tell you something neither test reveals alone: whether vascular damage is actively happening and whether your kidneys are part of the problem.

What This Panel Reveals

ADMA and SMDA are both produced when proteins inside your cells get broken down after being tagged with small chemical groups called methyl groups. Once released into the bloodstream, they take very different paths, and that difference is what makes measuring both so informative.

ADMA acts as a direct brake on nitric oxide production. It competes with the amino acid arginine for access to the enzyme (called nitric oxide synthase) that produces nitric oxide. When ADMA levels climb, less nitric oxide gets made. Blood vessels lose their ability to dilate on demand, the arterial lining becomes inflamed, and the earliest stages of atherosclerosis can take hold. The liver is the primary organ responsible for breaking ADMA down, using an enzyme called DDAH. Anything that stresses or inflames the liver can slow ADMA clearance.

SMDA takes a different route. It does not directly block nitric oxide synthase, but it competes with arginine for entry into cells, which can indirectly reduce the raw material available for nitric oxide production. The kidneys are almost entirely responsible for removing SMDA from the blood. As kidney filtration declines, SMDA rises in a tight, predictable relationship. A meta-analysis pooling data from multiple clinical studies found that SMDA correlates strongly with glomerular filtration rate (a measure of how effectively the kidneys filter blood per minute), the gold standard measure of kidney performance.

Why Measuring Both Matters More Than Measuring Either Alone

If you only measured ADMA, you would know that nitric oxide production is impaired, but you would not know why. Is it because the liver is not clearing ADMA fast enough? Is it because the kidneys are letting these molecules accumulate? Or is it because methylation (the chemical tagging process that creates these molecules) is unusually high, producing more of these byproducts than normal?

Adding SMDA answers the kidney question directly. When SMDA is elevated alongside ADMA, kidney clearance is likely part of the problem. When ADMA is high but SMDA is normal, the issue points toward increased production or impaired liver metabolism rather than kidney failure. That distinction changes the follow-up path entirely.

A large meta-analysis of prospective studies found that elevated ADMA was associated with a significantly higher risk of cardiovascular events and death from all causes. A separate pooled analysis confirmed that SMDA independently predicts cardiovascular events and total mortality as well, even after accounting for traditional risk factors. Together, these two markers capture overlapping but distinct dimensions of heart and kidney risk.

How to Read Your Results Together

Because this is a two-test panel, the interpretation patterns are straightforward. The table below shows the four possible combinations and what each suggests.

The ratio between the two tests also provides context. In healthy individuals, ADMA tends to circulate at slightly higher concentrations than SMDA. A shift where SMDA rises disproportionately relative to ADMA often signals early kidney filtration loss before creatinine or eGFR visibly change.

When Results Can Be Misleading

Acute illness, surgery, or severe infection can temporarily raise both ADMA and SMDA because body-wide inflammation increases protein breakdown and stresses both the liver and kidneys. If you are acutely sick when the blood is drawn, the results may overstate your baseline risk. Retesting four to six weeks after recovery gives a clearer picture.

Dehydration can concentrate blood levels and push both markers slightly higher. Certain medications, including some immunosuppressants, may also affect ADMA metabolism through the liver. If you take medications that affect liver enzymes, mention this to whoever reviews your results. Fasting status has minimal impact on these markers, but a consistent collection time (morning, fasted) reduces day-to-day variability.

Tracking Over Time

A single measurement tells you where you stand today. Serial measurements reveal the trajectory. A slowly rising ADMA level across two or three draws, even if each individual result is still within range, signals that your nitric oxide system is losing ground. That trend can prompt lifestyle changes, dietary adjustments (such as increasing arginine-rich foods), or closer cardiovascular monitoring before the numbers cross a clinical threshold.

SMDA is especially valuable as a tracking marker because of its tight relationship with kidney filtration. A gradual upward drift in SMDA can signal early kidney decline before conventional markers like creatinine move. For anyone with diabetes, hypertension, or a family history of kidney disease, serial SMDA tracking offers an early warning system.

What to Do with Your Results

If both markers are normal, you have reassuring evidence that your nitric oxide system and kidney clearance are intact.

If ADMA is elevated, consider adding a full lipid panel, hs-CRP (high-sensitivity C-reactive protein), and homocysteine to assess broader blood vessel inflammation and the chemical processes that generate these molecules. A liver function panel can help determine whether impaired ADMA clearance is contributing. Lifestyle changes that improve the health of the artery lining, including regular aerobic exercise and blood pressure management, have been associated with lower ADMA levels in clinical studies.

If SMDA is elevated, a kidney function panel including eGFR, cystatin C, and creatinine should be your next step. If kidney function is confirmed to be declining, early intervention with blood pressure control and metabolic management can slow progression.

If both are elevated, the combination suggests active heart and kidney risk. This pattern warrants a conversation with a physician who can evaluate both the cardiovascular and kidney dimensions together, rather than addressing either in isolation.